However, the dimensions of the global obesity and diabetes pandemics call for the development of new, effective, practical, and scalable treatments which will overcome the limitations of the GLP-1 analogues. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.